Fosaprepitant

Fosaprepitant

Clinical data
Trade names	Emend, Ivemend
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a604003
License data	EU EMA: by INN US DailyMed: Fosaprepitant US FDA: Fosaprepitant
Pregnancy category	AU: B2
Routes of administration	Intravenous
ATC code	A04AD12 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>95% (aprepitant)
Metabolism	To aprepitant
Elimination half-life	9 to 13 hours (aprepitant)
Identifiers
IUPAC name [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
CAS Number	172673-20-0 Y 265121-04-8 (dimeglumine)
PubChem CID	219090
IUPHAR/BPS	7623
DrugBank	DB06717 N
ChemSpider	189912 N
UNII	6L8OF9XRDC
KEGG	D06597 N
ChEBI	CHEBI:64321 N
ChEMBL	ChEMBL1199324 N
Chemical and physical data
Formula	C23H22F7N4O6P
Molar mass	614.414 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)Cc3[nH]c(=O)n(n3)P(=O)(O)O)c4ccc(cc4)F
InChI InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1 N Key:BARDROPHSZEBKC-OITMNORJSA-N N
NY (what is this?)  (verify)

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States, and in the European Union in January 2008.